Stockscreener 앱 받기
0.9612
19.85%
0.1592
시간 외 거래:
1.00
0.0388
+4.04%
Cytomx Therapeutics Inc 주식(CTMX)의 최신 뉴스
CytomX Therapeutics to Report First Quarter 2025 Financial Results on May 12, 2025 | CTMX Stock News - GuruFocus
CytomX Therapeutics to Report First Quarter 2025 Financial Results on May 12, 2025 - The Manila Times
Biotech Leader CytomX Sets Q1 2025 Earnings Date: Key Details for Investors - Stock Titan
CytomX Therapeutics Inc expected to post earnings of 12 cents a shareEarnings Preview - TradingView
CytomX Therapeutics Inc [CTMX] Stock sold by Insider McCarthy Sean A. for $22556.0 - knoxdaily.com
Get in on CytomX Therapeutics Inc’s (CTMX) buy-in window today! - Sete News
Press Release Distribution & PR Platform - ACCESS Newswire
Observations on the CytomX Therapeutics Inc (NASDAQ:CTMX) Growth Curve - uspostnews.com
Market Update: CytomX Therapeutics Inc (CTMX) Sees Negative Movement, Closing at 0.71 - DWinneX
Renaissance Technologies LLC Grows Stock Holdings in CytomX Therapeutics, Inc. (NASDAQ:CTMX) - Defense World
CytomX and Moderna unveil promising cancer therapy data By Investing.com - Investing.com Canada
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Shares Acquired by JPMorgan Chase & Co. - Defense World
CytomX Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update - ADVFN
Cytomx Therapeutics Presents Preclinical Data For mRNA Encoded Masked Il-12 Molecule In Collaboration With Moderna - marketscreener.com
CytomX Therapeutics Presents Preclinical Data for mRNA Encoded Masked IL-12 Molecule in Collaboration with Moderna at AACR Annual Meeting - The Manila Times
CytomX Unveils Breakthrough Cancer Treatment Data with Moderna at AACR | CTMX Stock News - Stock Titan
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Receives $4.77 Consensus Price Target from Brokerages - Defense World
CytomX Gears Up to Report Q1 Earnings: Here's What to Expect - MSN
Should investors be concerned about CytomX Therapeutics Inc (CTMX)? - uspostnews.com
CytomX Therapeutics Inc (CTMX)’s Market Momentum: Closing Strong at 0.73, Down -0.80 - DWinneX
CytomX Therapeutics Inc’s Shares Reel: -10.73% Quarterly Revenue Decline Amid 60.07M Market Cap - investchronicle.com
CytomX Therapeutics (NASDAQ:CTMX) Now Covered by Piper Sandler - Defense World
CytomX Therapeutics (NASDAQ:CTMX) Coverage Initiated by Analysts at StockNews.com - Defense World
Piper Sandler sets CytomX stock target at $2.50, rates Overweight By Investing.com - Investing.com Nigeria
CytomX Therapeutics (CTMX) Stock Poised for Growth Amid Clinical - GuruFocus
Piper Sandler Reaffirms Their Buy Rating on CytomX Therapeutics (CTMX) - The Globe and Mail
Piper Sandler sets CytomX stock target at $2.50, rates Overweight - Investing.com
New Outlook On CytomX Therapeutics Inc - stocksregister.com
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Shares Acquired by Prudential Financial Inc. - Defense World
CytomX Therapeutics Inc (NASDAQ: CTMX) 5.47% Incline Turns Investors Away - stocksregister.com
CTMX’s current quarter earnings: What analysts forecast? - uspostnews.com
Revenues Working Against CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Share Price Following 26% Dive - simplywall.st
CytomX stock hits 52-week low at $0.56 amid market challenges By Investing.com - Investing.com South Africa
CytomX stock hits 52-week low at $0.56 amid market challenges - Investing.com
Analysts Set CytomX Therapeutics, Inc. (NASDAQ:CTMX) Target Price at $5.02 - Defense World
Financial Metrics Check: CytomX Therapeutics Inc (CTMX)’s Ratios for Trailing Twelve Months - DWinneX
CytomX Therapeutics (NASDAQ:CTMX) Downgraded by StockNews.com to Hold - Defense World
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Shares Sold by Virtu Financial LLC - Defense World
StockNews.com Downgrades CytomX Therapeutics (NASDAQ:CTMX) to Hold - The AM Reporter
CytomX Therapeutics Faces Critical Challenges in Product Development and Market Viability - MSN
CytomX Therapeutics (CTMX) Upgraded to Strong Buy: Here's What You Should Know - MSN
CytomX therapeutics CFO Christopher Ogden sells $5,122 in stock - Investing.com India
CytomX therapeutics general counsel sells $6,111 in stock - Investing.com India
CytomX Therapeutics CMO Yu-Waye Chu sells shares for $2,410 By Investing.com - Investing.com Canada
Top Executives Cash Out: CytomX Therapeutics Stock Transactions Unveiled! - TipRanks
CytomX therapeutics CFO Christopher Ogden sells $5,122 in stock By Investing.com - Investing.com South Africa
CytomX Therapeutics CMO Yu-Waye Chu sells shares for $2,410 - Investing.com India
CytomX Therapeutics CEO sells $22,555 in stock By Investing.com - Investing.com South Africa
CytomX Therapeutics SVP Marcia Belvin sells $11,687 in stock - Investing.com India
CytomX Therapeutics SVP Marcia Belvin sells $11,687 in stock By Investing.com - Investing.com Canada
0.39%
3.66%
자본화:
|
볼륨(24시간):